disease-modifying antirheumatic drug

(redirected from Disease modifying antirheumatic drug)
Also found in: Acronyms.

disease-modifying antirheumatic drug (DMARD)

a classification of antirheumatic agents referring to their ability to modify the course of disease, as opposed to simply treating symptoms such as inflammation and pain. Agents in this group include auranofin, azathioprine, cycloSPORINE, gold salts, hydroxychloroquine, leflunomide, methotrexate, D-penicillamine, and sulfasalazine.

disease-modifying antirheumatic drug

DMARD Rheumatology Any agent–eg, azathioprine, gold, cyclophosphamide, hydroxychloroquin, and MTX–which slows the rate of joint destruction in rheumatoid arthritis

disease-modifying antirheumatic drug

Abbreviation: DMARD
A drug that is used to treat rheumatoid arthritis and acts more slowly but more effectively than nonsteroidal anti-inflammatory drugs. Such drugs include hydroxychloroquine, methotrexate, and tumor necrosis factor inhibitors.
Synonym: slow-acting antirheumatic drug
See also: drug
References in periodicals archive ?
HUMIRA is the only fully human monoclonal antibody approved by the FDA for reducing the signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active RA who have had insufficient response to one or more disease modifying antirheumatic drugs (DMARDs).
Food and Drug Administration (FDA) for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs) and can be used alone or in combination with methotrexate (MTX) or other DMARDs.
HUMIRA is the first human monoclonal antibody approved by the FDA for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs).
HUMIRA is the first human monoclonal antibody approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active RA who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs).
Food and Drug Administration has approved Kineret(TM) (anakinra) for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in adult patients who have failed one or more disease modifying antirheumatic drugs (DMARDs).
Kineret is for patients at least 18 years of age who have not responded to one or more drugs referred to as DMARDs or disease modifying antirheumatic drugs.
24-Week Results of a Blinded Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis

Full browser ?